USP30 — patent landscape

Top predicted compounds (top 20 by supporting neighbours, then confidence)

Compound	Confidence	Supporting neighbours
SCHEMBL387110	0.35	12/20
SCHEMBL242087	0.68	11/20
SCHEMBL242088	0.68	11/20
SCHEMBL91001	0.54	10/20
SCHEMBL357880	0.72	9/20
SCHEMBL330840	0.55	9/20
SCHEMBL330841	0.55	9/20
SCHEMBL463261	0.51	9/20
SCHEMBL386894	0.37	9/20
SCHEMBL268538	0.58	8/20
SCHEMBL268539	0.58	8/20
SCHEMBL269690	0.58	8/20
SCHEMBL90939	0.52	8/20
SCHEMBL70657	0.49	7/20
SCHEMBL120242	0.64	6/20
SCHEMBL121519	0.59	6/20
SCHEMBL407900	0.55	6/20
Trifluoroacetic Acid (SCHEMBL241707)	0.54	6/20
SCHEMBL189361	0.50	6/20
SCHEMBL269796	0.50	6/20

Clinical trials — most relevant to USP30 by text similarity (a relevance ranking, not an exhaustive list)

Trial	Phase	Status
Hypoxia-inducible Factor Prolyl Hydroxylase Inhibitors on Sarcopenia in Hemodialysis Patients	PHASE4	NOT_YET_RECRUITING
Can We Achieve 'high-quality' Weight Loss Through Supplementation and Exercise? the TRIM MUSCLE Study	PHASE3	COMPLETED
A Study of UBT251 in Participants With Metabolic Dysfunction-Associated Steatohepatitis (MASH)	PHASE2	RECRUITING
Desferal Administration to Improve the Impaired Reaction to Hypoxia in Diabetes	PHASE2	UNKNOWN
Alrizomadlin (APG-115) in Subjects With BAP1 Cancer Syndrome and Early-Stage Mesothelioma	PHASE2	WITHDRAWN
Decitabine/Cedazuridine (INQOVI), an Oral DNA Demethylating Agent, in Subjects With BAP1 Cancer Predisposition Syndrome and Subclinical, Early-Stage Mesothelioma	PHASE2	SUSPENDED
Effect of Deferoxamine on Wound Healing Rate in Patients With Diabetes Foot Ulcers	PHASE2	NOT_YET_RECRUITING
Relapsed and/or Refractory Non-Hodgkin Lymphoma Study	PHASE2	WITHDRAWN
The Effect of Roxadustat on Renal Oxygenation in Diabetes Nephropathy	PHASE2	NOT_YET_RECRUITING
Phase II Study of Vandetanib in Individuals With Kidney Cancer	PHASE2	COMPLETED
PS-341 and Radiation to Treat Advanced Cancer of the Head and Neck	PHASE1	COMPLETED
Testing the Safety of CB-5339 in Patients With Cancer	PHASE1	WITHDRAWN
Frequency and Clinical Phenotype of BAP1 Hereditary Predisposition Syndrome	nan	RECRUITING
Differential Gene Expression of Liver Tissue and Blood From Individuals With Chronic Viral Hepatitis	nan	UNKNOWN
Diagnostic Potential of UCHL1 in Acute Decompensated Heart Failure	nan	COMPLETED
Long Term Follow-Up of Patients With Mesothelioma and Individuals With Germline Mutations in BAP1	nan	RECRUITING
Effect of Dietary Nitrate on Immobilization-induced Changes in Skeletal Muscle in Young Healthy Men	nan	RECRUITING
Biomarkers in Tumor Samples From Younger Patients With Neuroblastoma	nan	COMPLETED
Clinical Study of 68Ga-DOTA-BLP PET Imaging in Noninvasive Diagnosis of Malignant Tumors	nan	NOT_YET_RECRUITING
Clinical Trial of Levodopa/Carbidopa ( Sinemet) Therapy in Angel Man Syndrome	nan	COMPLETED
The Role of RING Ubiquitin Ligases in Biologic and Oncologic Processes in Tissues of Mesenchymal Origin	nan	UNKNOWN
Low Dose Melphalan and Bortezomib for AML and High-Risk MDS	nan	COMPLETED
Evaluation of Prognostic Factors: From Breast Cancer to Bone Metastases	nan	UNKNOWN
Prospective Evaluation of High Resolution Dual Energy Computed Tomographic Imaging, Noninvasive (Liquid) Biopsies, and Minimally Invasive Surgical Surveillance for Early Detection of Mesotheliomas in Patients With BAP1 Tumor Predisposition Syndrome	nan	RECRUITING
Relationship Between Nutritional State and Respiratory Muscle Weakness in Adult Patients With Bronchietasis	nan	UNKNOWN
Inhibition of SENP1 for the Suppression of OS Growth and Metastasis	nan	UNKNOWN
Exercise Therapy to Reduce Heart Failure Symptoms; Sorting Mechanisms of Benefit	nan	COMPLETED
Autophagy in Systemic Lupus Erythematosus	nan	UNKNOWN
NLRP3 Inflammasome and Physical Therapy in ICU-Acquired Weakness	nan	RECRUITING
Drivers of Hypoxia-induced Angiogenesis in Tumor Development	nan	UNKNOWN

Related proteins — ESM-2 sequence neighbours (a USP30 binder may also engage these)

Protein	Name	Similarity
Q3UN04	—	0.999	Q3UN04 →
D3ZPG5	—	0.995	D3ZPG5 →
A4QNN3	—	0.992	A4QNN3 →
A2BGT0	—	0.988	A2BGT0 →
A5PN09	—	0.978	A5PN09 →
Q8C2S0	—	0.978	Q8C2S0 →
Q5XGZ2	—	0.978	Q5XGZ2 →
USP20	Ubiquitin carboxyl-terminal hydrolase 20	0.978	landscape →
Q8R5K2	—	0.978	Q8R5K2 →
Q8BW70	—	0.977	Q8BW70 →
A0JM59	—	0.976	A0JM59 →
A7Z056	—	0.975	A7Z056 →
Q8C6M1	—	0.974	Q8C6M1 →
A5PMR2	—	0.973	A5PMR2 →
Q6NTR6	—	0.973	Q6NTR6 →
Q28CN3	—	0.973	Q28CN3 →
D2HBJ8	—	0.973	D2HBJ8 →
Q8NB14	—	0.973	Q8NB14 →
A6QNM7	—	0.973	A6QNM7 →
Q9H0E7	—	0.971	Q9H0E7 →
Q5R5Z6	—	0.970	Q5R5Z6 →
B1WBD7	—	0.970	B1WBD7 →
Q8TEY7	—	0.970	Q8TEY7 →
E9QG68	—	0.969	E9QG68 →
B1AY15	—	0.969	B1AY15 →
Q9P2H5	—	0.969	Q9P2H5 →
Q8K387	—	0.969	Q8K387 →
Q5REG5	—	0.968	Q5REG5 →
Q5F479	—	0.967	Q5F479 →
Q7ZUM8	—	0.967	Q7ZUM8 →